	US 12,227,549 B2
	RNA encoding a therapeutic protein
Mariola Fotin-Mleczek, Sindelfingen (DE); and Ingmar Hoerr, Stuttgart (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Jun. 28, 2021, as Appl. No. 17/359,902.
Application 17/359,902 is a division of application No. 16/098,844, granted, now 11,078,247, issued on Aug. 3, 2021, previously published as PCT/EP2017/060692, filed on May 4, 2017.
Claims priority of application No. PCT/EP2016/060111 (WO), filed on May 4, 2016.
Prior Publication US 2022/0025369 A1, Jan. 27, 2022
Int. Cl. C07H 21/02 (2006.01); A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); C07H 21/04 (2006.01); C07K 14/505 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01)

CPC C07K 14/505 (2013.01) [A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); C12N 15/113 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2310/531 (2013.01)]

21 Claims

1. A method of treating or preventing propionic acidemia wherein, the method comprises administering to a subject in need thereof an effective amount of

a purified RNA comprising at least one coding sequence encoding a PCCA protein that is at least 95% identical to the amino acid sequence of SEQ ID NO: 8175, wherein the coding sequence comprises the nucleic acid sequence of any one of SEQ ID NOs: 34289, 47346, 60403, 21232 and 73460 or a sequence at least 80% identical to the nucleic acid sequence of any one of SEQ ID NOs: 34289, 47346, 60403, 21232 and 73460.